CPRX
Closed
Catalyst Pharmaceuticals Inc
21.19
-0.51 (-2.35%)
Last Update: 01 Jul 2025 23:18:00
Yesterday: 21.7
Day's Range: 21.1648 - 21.9799
Send
sign up or login to leave a comment!
When Written:
16.58
Catalyst Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes prescription drugs for rare neurological diseases. The company's lead product candidate is Firdapse, which is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder that affects the neuromuscular junction. Firdapse has been approved by the FDA for the treatment of LEMS and is currently being marketed in the United States.
The company was founded in 2002 and is headquartered in Coral Gables, Florida. Catalyst Pharmaceuticals has a team of experienced professionals in drug development, regulatory affairs, and commercialization. The company is committed to developing innovative therapies for rare diseases and improving the lives of patients who suffer from these conditions.
In addition to Firdapse, Catalyst Pharmaceuticals has a pipeline of other product candidates that are in various stages of development. These include CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other neurological disorders, and CPP-109, a drug that is being developed for the treatment of addiction and other neuropsychiatric disorders.
Catalyst Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol CPRX. The company has partnerships with leading academic institutions and research organizations to advance its drug development programs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company was founded in 2002 and is headquartered in Coral Gables, Florida. Catalyst Pharmaceuticals has a team of experienced professionals in drug development, regulatory affairs, and commercialization. The company is committed to developing innovative therapies for rare diseases and improving the lives of patients who suffer from these conditions.
In addition to Firdapse, Catalyst Pharmaceuticals has a pipeline of other product candidates that are in various stages of development. These include CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other neurological disorders, and CPP-109, a drug that is being developed for the treatment of addiction and other neuropsychiatric disorders.
Catalyst Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol CPRX. The company has partnerships with leading academic institutions and research organizations to advance its drug development programs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!